# US 11,439,605 B2 · Adrenaline pharmaceutical solution for an injection device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,439,605 B2
- Document ID: US11439605B2
- Status: Granted
- Kind: B2
- Application number: 17/604,124
- Filed: 2020-04-15
- Published: 2022-07-07
- Granted: 2022-09-13
- Earliest claimed: 2019-04-18
- Assignees: Crossject
- Applicants: Crossject
- Inventors: Eric Teillaud; Nicolas Baumard; Audrey Ressejeac
- Web page: https://patentgrep.com/patent/US11439605B2

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An adrenaline pharmaceutical solution including at least: adrenaline or a pharmaceutically-acceptable salt thereof; vitamin E TPGS; a chelating agent; a solvent. The method also relates to its use in the treatment of anaphylactic shocks, cardiac arrests, asthma and cardiocirculatory distresses. The method also concerns an injection kit including an injection device and this pharmaceutical solution.

## Claims

### Claim 1

An adrenaline pharmaceutical solution comprising at least:
adrenaline or a pharmaceutically-acceptable salt thereof;
D-alpha-tocopheryl polyethylene glycol succinate (hereinafter, abbreviated as «vitamin E TPGS»);
a chelating agent;
a solvent.

### Claim 2 (depends on 1)

The pharmaceutical solution according to claim 1, wherein the pharmaceutically-acceptable salt of adrenaline is selected from adrenaline tartrate and adrenaline hydrochloride.

### Claim 3 (depends on 2)

The pharmaceutical solution according to claim 2, wherein the pharmaceutically-acceptable salt of adrenaline is adrenaline tartrate.

### Claim 4 (depends on 1)

The pharmaceutical solution according to claim 1, wherein the chelating agent is selected from disodium ethylenediaminetetraacetate (hereinafter, abbreviated as «disodium EDTA»), ethylenediaminetetraacetic acid and disodium calcium ethylenediaminetetraacetate.

### Claim 5 (depends on 4)

The pharmaceutical solution according to claim 4, wherein the chelating agent is disodium EDTA.

### Claim 6 (depends on 1)

The pharmaceutical solution according to claim 1, wherein it further comprises at least one pH buffering agent which is selected from hydrochloric acid and soda.

### Claim 7 (depends on 1)

The pharmaceutical solution according to claim 1, wherein the pH of the pharmaceutical solution is comprised between 2.2 and 5.

### Claim 8 (depends on 1)

The pharmaceutical solution according to claim 1, wherein it further comprises at least one tonicity modifier which is sodium chloride.

### Claim 9 (depends on 1)

The pharmaceutical solution according to claim 1, wherein the adrenaline concentration in said pharmaceutical solution is comprised between 0.1 mg/mL and 1 mg/ml.

### Claim 10 (depends on 1)

The pharmaceutical solution according to claim 1, wherein it comprises in mg for 1 mL of the solution:
between 0.1 mg and 1 mg of adrenaline or of a pharmaceutically-acceptable salt thereof;
between 0.1 mg and 20 mg of vitamin E TPGS;
between 0.1 mg and 2 mg of a chelating agent;
Q.S. 1 mL of solvent.

### Claim 11 (depends on 1)

A process for preparing the pharmaceutical solution according to claim 1, wherein it comprises at least the following steps of:
a) preparing, under stirring, a mixture comprising all of the constituents of said solution except adrenaline or the pharmaceutically-acceptable salt of adrenaline so as to dissolve them;
b) dissolving adrenaline or a pharmaceutically-acceptable salt thereof in a solvent;
c) adding to the mixture of step a) the dissolved adrenaline or the dissolved pharmaceutically-acceptable salt thereof.

### Claim 12 (depends on 1)

A pharmaceutical solution according to claim 1 for its use in the treatment of anaphylactic shocks, cardiac arrests, asthma and cardiocirculatory distresses.

### Claim 13 (depends on 12)

The pharmaceutical solution according to claim 12, wherein said solution is in a form suitable for the administration by parenteral route.

### Claim 14 (depends on 1)

An injection kit including:
an injection device;
the pharmaceutical solution according to claim 1.

### Claim 15 (depends on 14)

The injection kit according to claim 14, wherein the injection device is a needleless injection device with a pyrotechnic cartridge.